AVEO Pharmaceuticals Stock Price

0.00 (0.0%)
Best deals to access real time data!
Big Cap Pro
Monthly Subscription
for only
Real-Time Alerts for Volume Breakouts, Highs and Lows for NYSE, NASDAQ, Amex, OTC Markets and OTCBB
Monthly Subscription
for only
Level 1 Starter
Monthly Subscription
for only
VAT not included
Company Name Stock Ticker Symbol Market Type
AVEO Pharmaceuticals Inc AVEO NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
0.00 0.0% 8.51 05:51:03
Open Price Low Price High Price Close Price Prev Close
Bid Price Ask Price Spread News
8.20 8.92 0.72 - -
Last Trade Time Type Quantity Stock Price Currency
- 0 $ 8.51 USD

AVEO Pharmaceuticals Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
$ 245.17M 28.81M 26.20M $ 28.80M $ - -0.11 -5.30
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- $ - 0.00% - -

more financials information »

AVEO Pharmaceuticals News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical AVEO Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week8.328.877.818.47350,2350.192.28%
1 Month8.139.707.818.69440,4230.384.67%
3 Months5.179.705.007.64412,8463.3464.6%
6 Months4.579.704.256.62415,9903.9486.21%
1 Year4.4613.012.23016.27503,7084.0590.81%
3 Years2.8413.010.4653221.772,140,7385.67199.65%
5 Years0.9813.010.4653222.051,969,1237.53768.37%

AVEO Pharmaceuticals Description

AVEO Pharmaceuticals Inc is a biopharmaceutical company dedicated to advancing a broad portfolio of targeted medicines for oncology and other areas of unmet medical need. The Company's aim is to retain North American rights to its oncology portfolio while securing partners in development and commercialization outside of North America. It is seeking to develop and commercialize its lead candidate tivozanib in North America as a treatment for advanced or metastatic renal cell carcinoma (RCC). It has outlicensed tivozanib (FOTIVDA) for oncology in Europe and other territories outside North America.

Your Recent History
AVEO Pharm..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.